ProPhase Labs, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ProPhase Labs, Inc. (PRPH) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $4.74 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-31
- ProPhase Labs, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $4.74M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2020-12-31 | $4.74M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |